2016 Drug Pipeline Full of Blockbuster Potential

2016 is expected to be a big year for first-time generics, with an estimated $20 billion targeted for going generic.

With several name brand drugs falling off patent, new biosimilars potentially gaining approval, and new treatments for cancer, diabetes and hepatitis C, 2016 is shaping up to be a blockbuster year for drugs to gain approval from the U.S. Food & Drug Administration.